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Abstract Focal adhesion kinase (FAK) is a protein tyrosine 
kinase implicated in signal transduction pathways for integrins, 
neuropeptides, and lysopbosphatidic acid. FAK, first discovered 
in non-neuronal cells, recently has been reported to occur in 
neurons, where its tyrosine phosphorylation is upregulated by 
fihronectin and by the Alzbeimer's A[~ peptide. The current work 
has elucidated molecular events leading to tyrosine pbospboryla- 
tion of FAK in the rat BI03 CNS nerve cell line. Activation of 
receptor-coupled G-proteins by Mas-7 was found to evoke rapid 
upregulation of FAK tyrosine phospborylation (Tyr(P)). Upreg- 
ulation by Mas-7 was blocked by GF109203X, a potent inhibitor 
of protein kinase C (PKC). Phorbol ester also upregulated FAK- 
YP, verifying a role for PKC in the transduction cascade. 
Upregulation of FAK-YP by activation of G-proteins and PKC 
was dependent upon intact F-actin, as cytochalasin D abolished 
stimulation by Mas-7 and by pborbol ester. The relatively slow 
increase in FAK-YP evoked by chronic exposure to A[3 also was 
abolished by GF109203X and by cytochalasin D. The results 
show that tyrosine phosphorylation of FAK in neurons is 
regulated positively by PKC, functioning down-stream from G- 
proteins through an F-actin-dependent mechanism. The Alzhei- 
mer's AI3 peptide is capable of activating elements of this same 
signal transduction pathway, via membrane vents that remain to 
be determined. 
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1. Introduction 
FAK is an intracellular protein tyrosine kinase that plays a 
central role in integrin-mediated signal transduction in non- 
neuronal cells [1]. It is coupled to intricate protein-protein 
interactions associated with filamentous actin and components 
of  focal adhesions [2]. Tyr(P) of  FAK  increases its own kinase 
activity and establishes a target sequence that can be bound 
by SH2 domains of other lattice-forming signal transduction 
proteins. Factors found to modulate FAK Tyr(P) now include 
lysophosphatidic acid, sphingosine, thrombin and various 
neuropeptides (vasopressin, endothelin, bombesin, and brady- 
kinin) [3,4]. 
Most work concerning FAK has been done in fibroblasts 
and platelets. Existence of FAK  in the nervous system was 
first indicated by the measurement of abundant FAK messen- 
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ger RNA in the brain [5]. The presence of FAK  protein re- 
cently has been established in nerve cell lines [6,7]. Neuronal 
FAK  is coupled to integrin-dependent neuritogenesis [8] and 
is developmentally regulated in the CNS [9]. Chronic exposure 
of rat and human nerve cell lines to the Alzheimer's A[3 pep- 
tide causes a non-sensitizing increase in FAK-YP  [6]. AI3- 
evoked FAK Tyr(P) correlates with neurotoxicity, with re- 
spect to dose kinetics, dependence on cell differentiation, 
and requirement for AI3 aggregation. 
Transduction mechanisms that influence FAK Tyr(P) in 
nerve cells have not been elucidated. In the current study, 
experiments with the B103 rat CNS nerve cell line show 
that G-protein activity can elevate FAK-YP  through a mech- 
anism dependent upon PKC and on the integrity of F-actin. 
Upregulation of FAK  Tyr(P) by the Alzheimer's A~ peptide 
appears to result from an impact of A~ on elements of this 
mechanism. 
2. Materials and methods 
Rat CNS B103 neuroblastoma cells were maintained in DMEM 
(Gibco/BRL), antibiotics (streptomycin, penicillin, and fungizone, 
Gibco/BRL), and 10% fetal calf serum (Sigma) in a 6% CO2 environ- 
ment. A~ peptides were synthesized and prepared as described [6]. For 
experiments with AI3 peptides, cells were plated on 100 mm Falcon 
tissue culture dishes at a density of 10 000-12,000 cells/cm 2 in a total 
volume of 4 ml. Cells were grown for 2448 h and then washed once 
with warm Hanks' basic salt solution before addition of the aged 
treatment solutions (DMEM and N2 supplement of Bottenstein and 
Sato in place of fetal calf serum) containing A[~ peptides or Me2SO. 
For experiments with Mas-7, phorbol ester, and cytochalasin D, B103 
cells were cultured at the same density, washed with warm Hanks' 
buffer, maintained in treatment solution. Agents or control vehicles 
were added directly to the cultures. After treatment with various 
agents, cell lysates were obtained and immunoprecipitation a d im- 
munoblot carried out with a standard protocol [6]. Briefly, the same 
amount of total protein from each sample was immunoprecipitated 
with anti-FAK polyclonal antibody (Upstate Biotechnology, Inc.), 
immunoprecipitated complexes were resolved with SDS-PAGE, and 
ECL Western blot was performed with anti-phosphotyrosine antibody 
RC20H (Transduction Laboratories). For re-probing experiments, 
membranes were stripped off antibodies by incubation in a solution 
containing 62.5 mM Tris-HC1, pH 6.7, 2% SDS, and 100 mM I]- 
mercaptoethanol at 55°C for 1-2 h. Then they were blotted with 
1:250 anti-FAK monoclonal antibody (Transduction Laboratories). 
Immunoreactive bands for the anti-FAK mAb were visualized using 
HRP-conjugated anti-mouse IgG secondary antibody and ECL re- 
agents. Film was analyzed with an LK B scanning densitometer which 
utilized the GelScan 2 program for integration of peaks. Film images 
were reproduced using a UMax scanner with the Aldus Photoshop 
imaging system. Unless specified, all chemicals were obtained from 
Sigma Chemical Co. 
3. Results and discussion 
It recently has been reported that G-protein(s) may play a 
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role in the stimulatory effect of LPA on FAK Tyr(P) [10]. Our 
first experiment ested the possibility that FAK Tyr(P) in 
neuronal cells could be elevated by direct activation of G- 
proteins. This as well as subsequent experiments employed 
the B103 nerve cell line, a spontaneously neuritogenic neuro- 
blastoma line cloned from the rat central nervous system [19] 
which has been utilized previously in studies of FAK  Tyr(P) 
[6]. Levels of FAK  Tyr(P) in B103 nerve cells were measured 
in the presence of increasing doses of Mas-7, a potent Go and 
Gi activator. B103 cell cultures maintained in DMEM and N2 
supplements were treated with increasing concentrations of 
Mas-7 for 1 h. The cells were lysed, and FAK was immuno- 
precipitated and analyzed with anti-phosphotyrosine ECL 
Western blot. As shown in Fig. 1A,B, Mas-7 stimulated 
FAK Tyr(P) in a dose-dependent manner, with half-maximal 
effect at 1.0 txM. The maximum increase was 3.7-fold. 
Effects of G-protein activity in many cases are mediated by 
downstream actions of protein kinase C. We therefore asked if 
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Fig. 1. Mas-7 treatment stimulates FAK Tyr(P) in a PKC-depen- 
dent manner. A: B103 cells were cultured in DMEM and N2 sup- 
plement and treated with 0, 0.1, 0.5, 1.0, 2.0, and 10 ~tM Mas-7 for 
1 h. Cells were lysed and FAK Tyr(P) levels were assayed with the 
standard protocol described in Section 2. The immunoblots how 
FAK Tyr(P) levels increasing in a dose-dependent manner. B: FAK 
Tyr(P) levels in A were quantified via densitometry and normalized 
to controls. The half-maximal response is approximately 1 ~tM and 
the increases due to Mas-7 ranged from 1.5- to a maximum of 3.7- 
fold. C: The dose-response curve of A was repeated in the presence 
of 3.5 /.tM GF109203X (indicated by +), a specific inhibitor of pro- 
tein kinase C. The left two lanes represent controls without 
GF109203X (indicated by -) .  The upper panel is a quantitative 
ECL immunoblot blot of FAK Tyr(P) and shows that GF109203X 
treatment blocked Mas-7's stimulation of FAK Tyr(P). The lower 
panel is a re-probe of the same membrane with anti-FAK antibody, 
and it verifies that equal amounts of FAK protein were present in 
each sample. 
C. Zhang et al./FEBS Letters 386 (1996) 185-188 
2 3 4 
+ + GFI09203X 
+ + PDBu 
~--  FAK Tyr (P) 
FAK protein 
Fig. 2. Phorbol ester activation of protein kinase C enhances FAK 
Tyr(P). B103 cell samples were treated with either 200 nM phorbol 
12,13-dibutyrate (lanes 2 and 3) or the same volume of solvent con- 
trol (lanes 1 and 4), for 10 min. Two samples (lanes 3 and 4) were 
simultaneously treated with 3.5 I.tM GF109203X. FAK protein and 
tyrosine phosphorylation levels were examined according to stand- 
ard protocol. The 10 min PDBu treatment increased Tyr(P) levels 
of FAK 2.3-fold; this effect was blocked by GF109203X. These re- 
sults demonstrate that PKC, directly or indirectly, can stimulate 
FAK Tyr(P). 
blocking PKC activity might inhibit the increase in FAK 
Tyr(P) caused by Mas-7. Cells were treated with or without 
the 3.5 ~tM GF109203X (bisindolylmaleimide), which has 
been determined previously to be a selective inhibitor of 
PKC [11]. As shown in the upper panel of Fig. 1C, Mas-7 
failed to stimulate FAK Tyr(P) in the presence of 
GF109203X. The membrane was stripped and reprobed with 
ant i -FAK mAb. As shown in the lower panel, increases in 
FAK protein level cannot account for the increases een in 
the anti-YP immunoblot. These results indicate that activation 
of G-proteins can effectively stimulate FAK Tyr(P) in B103 
nerve cells, and that this effect is mediated by PKC. 
To verify that PKC activity leads to upregulated FAK 
Tyr(P), we tested whether direct activation of PKC by phor- 
bol esters increased FAK Tyr(P). Cells were treated for 10 
min with 200 nM PDBu, a well characterized PKC activator. 
Control cells were treated with the same volume of chloro- 
form, in which PDBu was dissolved. Equal amounts of cellu- 
lar lysates were immunoprecipitated with ant i -FAK polyclo- 
nal antibody, and the immunoprecipitates were analyzed by 
immunoblotting with the HRP-conjugated anti-phosphotyro- 
sine antibody RC20H. As shown in the upper panel of Fig. 2, 
PDBu treatment resulted in a marked increase in FAK 
Tyr(P). Similar results were obtained in 5 other trials (data 
not shown), with a 2.4+0.2-fold increase in FAK Tyr(P) 
(P<0.05). These results show that direct activation of PKC 
in B103 cells can stimulate FAK Tyr(P). As would be ex- 
pected, the increase in Tyr(P) by PDBu was eliminated by 
simultaneous treatment with 3.5 ~tM GF109203X (lanes 3 
and 4 of Fig. 2). GF109203X kept the Tyr(P) level of FAK  
close to, or lower than the basal level (compare lanes 1, 3, and 
4 in Fig. 2). The lower panel of Fig. 2 shows that recovery of 
FAK  from cell lysates was not altered by treatment with 
PDBu. Thus increased PKC activity leads to upregulation of 
FAK  Tyr(P) in the B103 CNS nerve cell line. The specific 
PKC target(s) that leads to increased tyrosine phosphoryla- 
tion of FAK  is not known. 
FAK localizes to focal adhesions in non-neuronal cells [12], 
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Fig. 3. Actin cytoskeleton network is essential to PDBu's stimula- 
tion of FAK Tyr(P). B103 cells were treated with 200 nM PDBu or 
solvent control for 10 min. In the other two groups of samples, ceils 
were pretreated with 1.0 ~tM cytochalasin D or 0.5 l.tM colchicine. 
FAK protein and tyrosine phosphorylation levels were examined ac- 
cording to standard protocol. Cytochalasin D eliminated Mas-7 
stimulation of FAK Tyr(P), while colchicine had no effect. The ac- 
tin cytoskeletal network thus is required for the stimulation of FAK 
Tyr(P) by PDBu. 
interacts with actin-binding proteins uch as tensin and pax- 
illin [13], and appears to require compartmentalization f r 
activation [14]. These facts suggest hat integrity of F-actin 
networks might be necessary for the stimulation of FAK 
Tyr(P). We therefore tested the impact of cytochalasin D, 
which disrupts the actin cytoskeleton [15], on the upregulation 
of FAK Tyr(P) by PKC activity. B103 cell cultures were pre- 
treated with 1 ~tM cytochalasin D for 2 h and subsequently 
treated with 200 nM PDBu for 10 min. As a control, some 
B103 cell cultures were pretreated for 1 h with 0.5 laM colchi- 
cine, which depolymerizes microtubule filaments. The cells 
were then lysed, and FAK was immunoprecipitated and ana- 
lyzed with anti-phosphotyrosine ECL Western blot. As shown 
in Fig. 3, exposure to cytochalasin D eliminated the effect of 
PDBu on FAK Tyr(P). Although colchicine was observed to 
evoke neurite retraction, it had no effect on the ability of 
PDBu to stimulate FAK Tyr(P). The effect of cytochalasin 
D thus was specific for F-actin and was not due to a general 
disruption of the cytoskeleton. The immunoblot was stripped 
off antibody and reprobed with anti-FAK mAb, which 
showed similar recovery of FAK protein for each sample 
(lower panels). Cytochalasin D had no effect on cell viability. 
Analogous inhibition by cytochalasin D was observed for 
FAK Tyr(P) upregulation caused by Mas-7, as shown in 
Fig. 4. Pretreatment with colchicine did not alter the effect 
of Mas-7 (not shown). The F-actin cytoskeleton thus is essen- 
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Fig. 4. F-Actin cytoskeletal integrity is required for Mas-7 stimula- 
tion of FAK Tyr(P). B103 cells were treated with 1 I.tM Mas-7 or 
solvent control for 1 h. In the other two samples, cells were also 
pretreated with 1.0 ~tM cytochalasin D (Cyto D) for 2 h. Cytochala- 
sin D treatment eliminated Mas-7 stimulation of FAK Tyr(P), indi- 
cating the F-actin cytoskeleton is essential for G-protein upregula- 
tion of FAK Tyr(P). 
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Fig. 5. Stimulation of FAK Tyr(P) by A[3 1-42 is blocked by 
GF109203X and cytochalasin D. B103 cells were treated with 20 
txM aged AL3 peptides 1-42 or 17-42 for 1 day, with or without 3.5 
p_M GF109203X or 1.25 laM cytochalasin D. A[3 1-42 stimulated 
Tyr(P) levels of FAK 3.4-fold. These effects were blocked by 
GFI09203X and cytochalasin D. These results indicate that A[3 
stimulation of FAK Tyr(P) is dependent upon PKC and F-actin. 
tial for the G-protein, PKC-dependent upregulation of FAK 
Tyr(P). The data support a signal transduction model in 
which F-actin scaffolding coordinates a series of reactions 
that ultimately lead to tyrosine phosphorylation f FAK. 
We previously have shown that chronic exposure to the 
Alzheimer's A[3 peptide also stimulates FAK Tyr(P) in B103 
cells. Given the results described above, we therefore xam- 
ined the potential roles of PKC and the actin cytoskeletal 
network in mediating the Al3-stimulated upregulation of 
FAK Tyr(P). B103 cell cultures were treated with 20 /aM 
aged A[3 peptides 1-42 (neurotoxic), or 17-42 (non-toxic on- 
trol) for 1 day. The cells were lysed, and FAK was immuno- 
precipitated and analyzed with anti-phosphotyrosine ECL im- 
munoblot. As shown in Fig. 5 (left panel), AI3 1-42 treatment 
markedly increased FAK Tyr(P) in comparison to the control 
peptide 17-42. To test the role of PKC in stimulation of FAK 
Tyr(P) by A[3, 3.5 /aM GF109203X was added to cultures. 
Treatment with GF109203X completely inhibited the effects 
of AI 3 1-42, with no difference between 1-42 and 17-42 treat- 
ed samples. Membranes were stripped and blotted with anti- 
FAK antibody (lower panel), demonstrating that these treat- 
ments did not affect recovery of FAK from cell lysates. Simi- 
lar experiments were performed to test the necessity of actin 
cytoskeleton for AI3 aggregates' timulation of FAK Tyr(P). 
B103 cell samples were treated with either 20 p.M A[3 1-42 
aggregates or 20 gM of its reversed form simultaneously with 
1.25 /aM cytochalasin D for 1 day. The cells were lysed and 
FAK was immunoprecipitated and analyzed with an anti- 
phosphotyrosine ECL immunoblot. As shown in Fig. 5 (right 
panel), cytochalasin D effectively blocked A[3 1~,2 aggregates' 
stimulation of FAK Tyr(P). Colchicine treatment did not alter 
the effect of AI3 (not shown). These data show that AI3 stimu- 
lates tyrosine phosphorylation f FAK via a mechanism that 
shares elements of an F-actin-dependent signal transduction 
pathway. How AI3 triggers the F-actin and PKC-dependent 
cascade leading to FAK Tyr(P) is unknown. Since AI3 fibrils 
can attach to cell surfaces [16], one possibility is that mem- 
brane perturbations lead to G-protein activation. Promotion 
of a minor Ca 2+ leak [17] might theoretically ead to the same 
response. 
Of particular significance is the emerging link between AI3 
and F-actin-dependent signal transduction. It now is well re- 
cognized that F-actin-dependent signaling plays a central role 
in regulatory cell biology [2]. Various lines of evidence also 
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indicate a role for actin-associated signaling in synaptic plas- 
ticity [18]. By disrupting multifunctional F-actin-dependent 
transduction, AI3 could have a profound effect on neurons, 
giving rise to dementia or memory loss by causing cell death 
or dysfunction in synaptic plasticity. 
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